These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 34338634)

  • 1. The development of
    Ye G; Gallant J; Zheng J; Massey C; Shi K; Tai W; Odle A; Vickers M; Shang J; Wan Y; Du L; Aihara H; Perlman S; LeBeau A; Li F
    Elife; 2021 Aug; 10():. PubMed ID: 34338634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Development of a Novel Nanobody Therapeutic for SARS-CoV-2.
    Ye G; Gallant JP; Massey C; Shi K; Tai W; Zheng J; Odle AE; Vickers MA; Shang J; Wan Y; Drelich A; Kempaiah KR; Tat V; Perlman S; Du L; Tseng CT; Aihara H; LeBeau AM; Li F
    bioRxiv; 2020 Nov; ():. PubMed ID: 33236012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Nanosota-2, -3, and -4 as super potent and broad-spectrum therapeutic nanobody candidates against COVID-19.
    Ye G; Pan R; Bu F; Zheng J; Mendoza A; Wen W; Du L; Spiller B; Wadzinski BE; Liu B; Perlman S; Li F
    J Virol; 2023 Nov; 97(11):e0144823. PubMed ID: 37855638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.
    Huo J; Le Bas A; Ruza RR; Duyvesteyn HME; Mikolajek H; Malinauskas T; Tan TK; Rijal P; Dumoux M; Ward PN; Ren J; Zhou D; Harrison PJ; Weckener M; Clare DK; Vogirala VK; Radecke J; Moynié L; Zhao Y; Gilbert-Jaramillo J; Knight ML; Tree JA; Buttigieg KR; Coombes N; Elmore MJ; Carroll MW; Carrique L; Shah PNM; James W; Townsend AR; Stuart DI; Owens RJ; Naismith JH
    Nat Struct Mol Biol; 2020 Sep; 27(9):846-854. PubMed ID: 32661423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction.
    Hanke L; Vidakovics Perez L; Sheward DJ; Das H; Schulte T; Moliner-Morro A; Corcoran M; Achour A; Karlsson Hedestam GB; Hällberg BM; Murrell B; McInerney GM
    Nat Commun; 2020 Sep; 11(1):4420. PubMed ID: 32887876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry.
    Ge J; Wang R; Ju B; Zhang Q; Sun J; Chen P; Zhang S; Tian Y; Shan S; Cheng L; Zhou B; Song S; Zhao J; Wang H; Shi X; Ding Q; Liu L; Zhao J; Zhang Z; Wang X; Zhang L
    Nat Commun; 2021 Jan; 12(1):250. PubMed ID: 33431856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural Basis for Evasion of New SARS-CoV-2 Variants from the Potent Virus-Neutralizing Nanobody Targeting the S-Protein Receptor-Binding Domain.
    Sluchanko NN; Shcheblyakov DV; Varfolomeeva LA; Favorskaya IA; Dolzhikova IV; Korobkova AI; Alekseeva IA; Esmagambetov IB; Derkaev AA; Prokofiev VV; Zorkov ID; Logunov DY; Gintsburg AL; Popov VO; Boyko KM
    Biochemistry (Mosc); 2024 Jul; 89(7):1260-1272. PubMed ID: 39218023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A broad neutralizing nanobody against SARS-CoV-2 engineered from an approved drug.
    Liu Q; Lu Y; Cai C; Huang Y; Zhou L; Guan Y; Fu S; Lin Y; Yan H; Zhang Z; Li X; Yang X; Yang H; Guo H; Lan K; Chen Y; Hou SC; Xiong Y
    Cell Death Dis; 2024 Jun; 15(6):458. PubMed ID: 38937437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection.
    Li T; Cai H; Yao H; Zhou B; Zhang N; van Vlissingen MF; Kuiken T; Han W; GeurtsvanKessel CH; Gong Y; Zhao Y; Shen Q; Qin W; Tian XX; Peng C; Lai Y; Wang Y; Hutter CAJ; Kuo SM; Bao J; Liu C; Wang Y; Richard AS; Raoul H; Lan J; Seeger MA; Cong Y; Rockx B; Wong G; Bi Y; Lavillette D; Li D
    Nat Commun; 2021 Jul; 12(1):4635. PubMed ID: 34330908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response.
    Liu Z; Xu W; Xia S; Gu C; Wang X; Wang Q; Zhou J; Wu Y; Cai X; Qu D; Ying T; Xie Y; Lu L; Yuan Z; Jiang S
    Signal Transduct Target Ther; 2020 Nov; 5(1):282. PubMed ID: 33247109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice.
    Pymm P; Adair A; Chan LJ; Cooney JP; Mordant FL; Allison CC; Lopez E; Haycroft ER; O'Neill MT; Tan LL; Dietrich MH; Drew D; Doerflinger M; Dengler MA; Scott NE; Wheatley AK; Gherardin NA; Venugopal H; Cromer D; Davenport MP; Pickering R; Godfrey DI; Purcell DFJ; Kent SJ; Chung AW; Subbarao K; Pellegrini M; Glukhova A; Tham WH
    Proc Natl Acad Sci U S A; 2021 May; 118(19):. PubMed ID: 33893175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of single-domain antibodies (or nanobodies) in SARS-CoV-2 neutralization.
    Zebardast A; Hosseini P; Hasanzadeh A; Latifi T
    Mol Biol Rep; 2022 Jan; 49(1):647-656. PubMed ID: 34648139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of Critical Determinants of ACE2-SARS CoV-2 RBD Interaction.
    Brown EEF; Rezaei R; Jamieson TR; Dave J; Martin NT; Singaravelu R; Crupi MJF; Boulton S; Tucker S; Duong J; Poutou J; Pelin A; Yasavoli-Sharahi H; Taha Z; Arulanandam R; Surendran A; Ghahremani M; Austin B; Matar C; Diallo JS; Bell JC; Ilkow CS; Azad T
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33668756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19.
    Esparza TJ; Chen Y; Martin NP; Bielefeldt-Ohmann H; Bowen RA; Tolbert WD; Pazgier M; Brody DL
    MAbs; 2022; 14(1):2047144. PubMed ID: 35289719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure and function analysis of a potent human neutralizing antibody CA521
    Song D; Wang W; Dong C; Ning Z; Liu X; Liu C; Du G; Sha C; Wang K; Lu J; Sun B; Zhao Y; Wang Q; Xu H; Li Y; Shen Z; Jiao J; Wang R; Tian J; Liu W; Wang L; Deng YQ; Dou C
    Commun Biol; 2021 Apr; 4(1):500. PubMed ID: 33893388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme.
    Esparza TJ; Martin NP; Anderson GP; Goldman ER; Brody DL
    Sci Rep; 2020 Dec; 10(1):22370. PubMed ID: 33353972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Potent Neutralizing Nanobody Targeting the Spike Receptor-Binding Domain of SARS-CoV-2 and the Structural Basis of Its Intimate Binding.
    Yang J; Lin S; Sun H; Chen Z; Yang F; Lin X; Guo L; Wang L; Wen A; Zhang X; Dai Y; He B; Cao Y; Dong H; Liu X; Chen B; Li J; Zhao Q; Lu G
    Front Immunol; 2022; 13():820336. PubMed ID: 35663966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
    Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.
    Yi C; Sun X; Ye J; Ding L; Liu M; Yang Z; Lu X; Zhang Y; Ma L; Gu W; Qu A; Xu J; Shi Z; Ling Z; Sun B
    Cell Mol Immunol; 2020 Jun; 17(6):621-630. PubMed ID: 32415260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.